Management during cardiopulmonary bypass of patients with presumed fish allergy

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 15, Issue 4, 2001, Pages 512-519

  Mukadam, M E ^a,b,c   Pritchard, P ^a,b,c   Riddington, D ^a,b,c   Wilkes, M ^a,b,c   Graham, T R ^a,b,c   Horrow, Jay Charles ^a,b,c   Spiess, Bruce D ^a,b,c  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fish allergy; Heparin coated cardiopulmonary bypass; Low systemic heparinization; Protamine

Indexed keywords

HEPARIN; PROTAMINE SULFATE; ANTICOAGULANT AGENT; BIOMATERIAL; HEPARIN ANTAGONIST; PROTAMINE;

AGED; BLEEDING; BLOOD CLOTTING TIME; CARDIOPULMONARY BYPASS; CASE REPORT; CONFERENCE PAPER; FISH; FOOD ALLERGY; HEART CATHETERIZATION; HEPARINIZATION; HUMAN; MALE; PRIORITY JOURNAL; SURGICAL APPROACH; TREATMENT CONTRAINDICATION; ANIMAL; ARTICLE; CLINICAL OBSERVATION; CLINICAL STUDY; CORONARY ARTERY BYPASS GRAFT; CROSS REACTION; DIAGNOSIS; DRUG HYPERSENSITIVITY; HEART VALVE REPLACEMENT; IMMUNOLOGY; INSTRUMENTATION; PREOPERATIVE CARE; SKIN TEST;

AGED; ANIMALS; ANTICOAGULANTS; CARDIOPULMONARY BYPASS; COATED MATERIALS, BIOCOMPATIBLE; CORONARY ARTERY BYPASS; CROSS REACTIONS; DRUG HYPERSENSITIVITY; FISHES; FOOD HYPERSENSITIVITY; HEART VALVE PROSTHESIS IMPLANTATION; HEPARIN; HEPARIN ANTAGONISTS; HUMANS; MALE; PREOPERATIVE CARE; PROTAMINES; SKIN TESTS;

EID: 0035431001     PISSN: 10530770     EISSN: None     Source Type: Journal    
DOI: 10.1053/jcan.2001.25006     Document Type: Conference Paper

References (80)

1. Protamine: A review of its toxicity
2. Hemodynamic changes during protamine administration
3. Cardiovascular effects of protamine sulfate in man
4. Protamine and left ventricular function: A transoesophageal echocardiography study
5. Association of protamine IgE and IgG antibodies with life-threatening reactions to intravenous protamine
6. An anaphylactic reaction to protamine in a patient allergic to fish
7. Protamine allergy reactions during cardiac catheterization and cardiac surgery: Risk in patients taking protamine-insulin preparations
8. C5a and thromboxane generation associated with pulmonary vaso- and bronchoconstriction during protamine reversal of heparin
9. Adverse reactions to protamine sulphate during cardiac surgery in diabetic and nondiabetic patients
10. Evaluation of patients at risk for protamine reactions
11. Protamine sulphate and fish allergy
12. Protamine sulphate hypersensitivity
13. A prospective study of the risk of an immediate adverse reaction to protamine sulfate during cardiopulmonary bypass surgery
14. Must heparin be neutralised following openheart operations?
15. Prophylactic administration of histamine 1 and/or histamine 2 receptor blockers in the prevention of heparin and protamine related haemodynamic effects
16. The use of a heparin removal device: A valid alternative to protamine
17. Heparin-coated cardiopulmonary bypass circuits: Hemostatic alterations and postoperative blood loss
18. Completely heparinised cardiopulmonary bypass and reduced systemic heparinisation: Clinical and hemostatic effects
19. Decreased blood loss after cardiopulmonary bypass using heparin-coated circuit and 50% reduction of heparin dose
20. Reduction and elimination of systemic heparinisation during cardiopulmonary bypass
21. Characterisation of protamine activation during cardiac surgery by hemostatic molecular markers
22. Heparin-coated circuit during cardiopulmonary bypass: A clinical study using closed circuit, centrifugal pump and reduced heparinisation
23. Comparision of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations
24. Prospective evaluation of patients with fish allergies for anaphylaxis to protamine
25. Allergic reactions to fish
26. Protamine allergy
27. Allergic reactions during anesthesia
28. Intradermal testing in the diagnosis of acute anaphylaxis during anesthesia - Results of five years' experience
29. Neither skin tests nor serum enzyme-linked immunosorbent assay tests provide specificity for protamine allergy
30. Intradermal testing and anaphylactoid reaction to anaesthetic drugs: Practical aspects of performance and interpretation
31. Heparin neutralization by recombinant platelet factor 4 and protamine
32. Heparin degradation by a novel microbial heparinase
33. Efficacy and toxicity of differently charged polycationic protamine-like peptides for heparin anticoagulation reversal
34. Low activated coagulation time during cardiopulmonary bypass does not increase postoperative bleeding
35. Coagulation transfusion and cardiac surgery
36. A reevealuation of heparin requirements for cardiopulmonary bypass
37. Heparin management protocol for cardiopulmonary bypass influences postoperative heparin rebound but not bleeding
38. The impact of heparin concentration and activated clotting time monititoring on blood conservation: A prospective, randomized evaluation in patients undergoing cardiac operation
39. Protease inhibitors of human plasma: Antithrombin III: "The heparin antithrombin III system."
40. Differential effects of anticoagulants on the activation of platelets ex vivo
41. Fucoida, as heparin, induces tissue factor pathway inhibitor release from cultured human endothelial cells
42. Heparinbinding vitronectin up-regulates latent TGF-beta production by bovine aortic endothelial cells
43. Heparin: Beyond an anticoagulant
44. Unfractionated heparin for cardiopulmonary bypass: An unnatural act?
45. Recombinant Hirudin as an alternative for anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: A 1-year experience in 57 patients
46. Hirudin monitoring using the TAS ecarin clotting time in patients with heparin-induced thrombocytopenia type II
47. Comparison of two PF4/heparin ELISA assays for the laboratory diagnosis of heparininduced thrombocytopenia
48. The effect of protamine sulfate on platelet function
49. Thrombocytopenia accompanying a reaction to protamine sulfate
50. Cardiopulmonary bypass leads to a preferential loss of activated platelets: A flow cytometric assay of platelet surface antigens
51. Platelet protection in coronary artery surgery: Benefits of heparin-coated circuits and high-dose aprotinin therapy
52. Synthetic protein treated versus heparin-coated cardiopulmonary bypass surfaces: Similar clinical results and minor biochemical differences
53. Trillium coating of cardiopulmonary bypass circuits improves biocompatibility
54. The effects of heparincoating of oxygenator fibers on platelet adhesion and protein adsorption
55. Evaluation of heparin-coated circuits with full heparin dose strategy
56. Activation of coagulation and fibrinolysis during cardiothoracic operations
57. Relationship of fibrinolysis and platelet function to bleeding after cardiopulmonary bypass
58. Individual variations in the fibrinolytic response during and after cardiopulmonary bypass
59. Heparin-coated bypass circuit (Carmeda) suppresses the release of tissue plasminogen activator during normothermic coronary artery bypass graft surgery
60. Perioperative course and recovery after heparin-coated cardiopulmonary bypass: Low-dose versus high-dose heparin management
61. Heparin coating with aprotinin reduces blood activation during coronary artery operations
62. Use of heparin-coated cardiopulmonary bypass circuit with low-dose heparin reduces postoperative bleeding
63. Coagulofibrinolysis during heparin-coated cardiopulmonary bypass with reduced heparinization
64. Heparin-coated cardiopulmonary bypass equipment: II. Mechanisms for reduced complement activation in vivo
65. Heparin-coated cardiopulmonary bypass circuits reduce circulating complement factors and interleukin 6 in paediatric heart surgery
66. Clinical efficacy of heparin-bonded bypass circuits related to cytokine response in children
67. Superior biocompatibility of heparin-bonded circuits in pediatric cardiopulmonary bypass
68. No benefit of reduced heparinization in thoracic aortic operation with heparin-coated bypass circuits
69. Heparin-coated circuits reduce occult myocardial damage during CPB: A randomized single blind clinical trial
70. Heparin coating of extracorporeal circuits inhibits cytokine release from mononuclear cells during cardiac operations
71. Cytokine release and neutrophil activation are not prevented by heparin-coated circuits and aprotinin administration
72. Effects of Duraflo II heparin-coated cardiopulmonary bypass circuits on the coagulation system, endothelial damage, and cytokine release in patients with cardiac operation employing aprotinin and steroids
73. Quantitiative evaluation of heparin-coated versus non-heparin-coated bypass circuits during cardiopulmonary bypass
74. Pro: Heparin-bonded circuits represent a desirable option for cardiopulmonary bypass
75. Con: Heparin-bonded cardiopulmonary bypass circuits do not represent a desirable and cost-effective advance in cardiopulmonary bypass technology
76. Use of heparin-coated cardiopulmonary bypass circuit with low-dose heparin reduces postoperative bleeding
77. Coagulation and inflammation polymorphism: Impact on cardiovascular outcomes
78. Complement activation during storage of preserved blood
79. Heparin-coated circuits: A new prospective - The boundary layer